|
|
|
|
LEADER |
03666nam a2200937Ia 4500 |
001 |
10-2217-fca-2021-0091 |
008 |
220420s2022 CNT 000 0 und d |
020 |
|
|
|a 14796678 (ISSN)
|
245 |
1 |
0 |
|a Living with hypertrophic cardiomyopathy: A patient's perspective
|
260 |
|
0 |
|b Future Medicine Ltd.
|c 2022
|
300 |
|
|
|a 8
|
856 |
|
|
|z View Fulltext in Publisher
|u https://doi.org/10.2217/fca-2021-0091
|
520 |
3 |
|
|a Hypertrophic cardiomyopathy (HCM) is a complex disease characterized by thickening of the cardiac muscle. Common symptoms include chest pain, shortness of breath, palpitations, fatigue and syncope (fainting), which are often confused for other conditions. Clinical treatment focuses on the relief of symptoms with medical therapies, which provide adequate to more variable symptomatic relief. Patients may experience more severe complications that require surgical intervention, such as implantable cardioverter-defibrillator therapy or septal myectomy. Despite the potential impact on quality of life, the humanistic burden of HCM is not well established. Here, we present four patient testimonials that highlight challenges faced by patients and clinicians in diagnosing HCM and managing symptoms. These testimonials provide valuable information on the spectrum and expression of HCM across generations. Such testimonials can better inform disease diagnosis and monitoring, maximizing quality of life and improving disease outcome. © 2021 The Authors.
|
650 |
0 |
4 |
|a acetylsalicylic acid
|
650 |
0 |
4 |
|a adolescent
|
650 |
0 |
4 |
|a adult
|
650 |
0 |
4 |
|a Arrhythmias, Cardiac
|
650 |
0 |
4 |
|a Article
|
650 |
0 |
4 |
|a atenolol
|
650 |
0 |
4 |
|a backache
|
650 |
0 |
4 |
|a beta adrenergic receptor blocking agent
|
650 |
0 |
4 |
|a Cardiomyopathy, Hypertrophic
|
650 |
0 |
4 |
|a cardiovascular magnetic resonance
|
650 |
0 |
4 |
|a case report
|
650 |
0 |
4 |
|a cerebrovascular accident
|
650 |
0 |
4 |
|a child
|
650 |
0 |
4 |
|a clinical article
|
650 |
0 |
4 |
|a clinician
|
650 |
0 |
4 |
|a colecalciferol
|
650 |
0 |
4 |
|a Defibrillators, Implantable
|
650 |
0 |
4 |
|a diltiazem
|
650 |
0 |
4 |
|a dizziness
|
650 |
0 |
4 |
|a drug dose increase
|
650 |
0 |
4 |
|a dyspnea
|
650 |
0 |
4 |
|a echocardiography
|
650 |
0 |
4 |
|a emergency ward
|
650 |
0 |
4 |
|a endocarditis
|
650 |
0 |
4 |
|a faintness
|
650 |
0 |
4 |
|a fatigue
|
650 |
0 |
4 |
|a female
|
650 |
0 |
4 |
|a fluid retention
|
650 |
0 |
4 |
|a furosemide
|
650 |
0 |
4 |
|a headache
|
650 |
0 |
4 |
|a heart arrhythmia
|
650 |
0 |
4 |
|a heart left bundle branch block
|
650 |
0 |
4 |
|a heart murmur
|
650 |
0 |
4 |
|a heart outflow tract obstruction
|
650 |
0 |
4 |
|a human
|
650 |
0 |
4 |
|a Humans
|
650 |
0 |
4 |
|a hypertrophic cardiomyopathy
|
650 |
0 |
4 |
|a hypertrophic cardiomyopathy
|
650 |
0 |
4 |
|a hypertrophic cardiomyopathy
|
650 |
0 |
4 |
|a implantable cardioverter defibrillator
|
650 |
0 |
4 |
|a implantable cardioverter defibrillator
|
650 |
0 |
4 |
|a knee meniscus rupture
|
650 |
0 |
4 |
|a lead fracture
|
650 |
0 |
4 |
|a magnesium
|
650 |
0 |
4 |
|a middle aged
|
650 |
0 |
4 |
|a milrinone
|
650 |
0 |
4 |
|a muscle resection
|
650 |
0 |
4 |
|a paracetamol
|
650 |
0 |
4 |
|a patient care
|
650 |
0 |
4 |
|a patient experience
|
650 |
0 |
4 |
|a patient monitoring
|
650 |
0 |
4 |
|a perception
|
650 |
0 |
4 |
|a postoperative pain
|
650 |
0 |
4 |
|a quality of life
|
650 |
0 |
4 |
|a Quality of Life
|
650 |
0 |
4 |
|a school child
|
650 |
0 |
4 |
|a septal myectomy
|
650 |
0 |
4 |
|a sudden death
|
650 |
0 |
4 |
|a thorax pain
|
650 |
0 |
4 |
|a verapamil
|
650 |
0 |
4 |
|a water retention
|
650 |
0 |
4 |
|a wheezing
|
700 |
1 |
0 |
|a Borsari, W.
|e author
|
700 |
1 |
0 |
|a Davis, L.
|e author
|
700 |
1 |
0 |
|a McDonough, B.
|e author
|
700 |
1 |
0 |
|a Meiers, E.
|e author
|
700 |
1 |
0 |
|a Salberg, L.
|e author
|
773 |
|
|
|t Future Cardiology
|